Cargando…
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
Background: We evaluated the association between pathogenic mutations and overall survival (OS) in patients with cancer referred to Hellenic Cooperative Oncology Group–affiliated Departments. Patients and methods: Patients referred from 12/1980 to 1/2017 had molecular testing (for research) of archi...
Autores principales: | Fountzilas, Elena, Kotoula, Vassiliki, Koliou, Georgia-Angeliki, Giannoulatou, Eleni, Gogas, Helen, Papadimitriou, Christos, Tikas, Ioannis, Zhang, Jianhua, Papadopoulou, Kyriaki, Zagouri, Flora, Christodoulou, Christos, Koutras, Angelos, Makatsoris, Thomas, Chrisafi, Sofia, Linardou, Helena, Varthalitis, Ioannis, Papatsibas, George, Razis, Evangelia, Papakostas, Pavlos, Samantas, Epaminontas, Aravantinos, Gerasimos, Bafaloukos, Dimitrios, Kosmidis, Paris, Koumarianou, Anna, Psyrri, Amanda, Pentheroudakis, Georgios, Pectasides, Dimitrios, Futreal, Andrew, Fountzilas, George, Tsimberidou, Apostolia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967777/ https://www.ncbi.nlm.nih.gov/pubmed/32002119 http://dx.doi.org/10.18632/oncotarget.27338 |
Ejemplares similares
-
Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018) -
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019) -
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014) -
Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
por: Fountzilas, Elena, et al.
Publicado: (2021) -
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)